Connect with us

Biotech

The City Council partners with AEBA to convert Alicante into a biotech cluster

The Association of Biotechnological Companies shows its interest in concentrating biotechnological companies in the city and promoting public-private collaboration. The Councilor for Employment and Local Development and the president of AEBA are now working to finalize a proposal for the development of the biotech cluster in Alicante, with tangible results in a short period of time.

Published

on

This picture show a city in Spain.

The Councilor for Employment and Development, Mari Carmen from Spain, has taken a step forward through the Local Development Agency to make Alicante a benchmark in the biotechnology industry and thus promote the development of the new innovative economy within the strategy ‘Alicante Futura’. 

She has met with the President of the Association of Biotechnology Companies (AEBA) of the province of Alicante, Andrés Antón, and members of its Board of Directors in the process to consolidate a biotech cluster in the Alicante capital.

If you want to read more about the biotech sector in Spain and how the City Council of Alicante together with the Association of Biotechnological Companies (AEBA) want to transform the city into a biotech cluster, download for free the Born2Invest mobile app. Read the latest business news and stay on top of the market with our companion app.

The importance of the Spanish biotech sector 

Mari Carmen explained: “We have been working for more than a year with biotechnology companies to favor environmental conditions so that Alicante becomes a benchmark in the sector at a national and international level, coordinating efforts and resources to establish a sector in our capital that is one of the backbones of the ‘Alicante Futura’ strategy. Our objective is to turn the city into the capital of the technology industry, entrepreneurship and innovation and the new urban economy.”

“We have held a meeting with Andrés Antón, president of AEBA, and his Board of Directors, with whom we continue working to attend to the interest of the sector in promoting a concentration of companies in the city of Alicante,” she commented, adding that “This emerging business cluster would allow the generation of synergies between its actors, enhance the economy and quality local employment, especially of women and specialized profiles, in addition to taking an important step in attracting companies and promoting the innovative, digital and technological economy.”

The Local Agency for Economic and Social Development ‘ImpulsAlicante’ has been the scene, during the last year, of different meetings with the companies in the biotech sector, the last of which, the ‘Alicante, Biotech Territory’ Forum at the end of February with the presence of the main executives of the companies in the sector. During this forum, the growth potential and future projection of Alicante Biotechnology and the alignment of objectives between the Department led by Spain and a sector that is one of the most valuable gems of the new post-COVID economy was highlighted.

In the same way, Spain has highlighted the commitment acquired by the City Council to promote public-private collaboration, especially in these times of pandemic, as one of the axes on which the ‘Alicante Futura’ strategy pivots as the engine of transformation of the country’s economic model and vehicle for attracting new innovative and job-creating companies. These are the two of the main pillars on which the work carried out by the Local Development Agency for the economic and social recovery of the city is based.

The Councilor for Employment and Local Development and the president of AEBA are now working to finalize a proposal for the development of the Biotech Cluster in Alicante, with tangible results in a short period of time.

__

(Featured image by manusama via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in elperiodic, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.